Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Issue 5 (17th July 2014)

• Record Type: Journal Article
• Authors: Duits, Lucas C; Phoa, K Nadine; Curvers, Wouter L; ten Kate, Fiebo J W; Meijer, Gerrit A; Seldenrijk, Cees A; Offerhaus, G Johan; Visser, Mike; Meijer, Sybren L; Krishnadath, Kausilia K; Tijssen, Jan G P; Mallant-Hent, Rosalie C; Bergman, Jacques J G H M
• Is Part Of: Gut. Volume 64:Issue 5(2015)
• Page Start: 700
• Page End: 706
• Publication Date: 2014-07-17
• Subjects: Oesophageal Cancer -- Barrett's Carcinoma -- Barrett's Oesophagus -- Dysplasia -- Histopathology; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2014-307278
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Reported malignant progression rates for low-grade dysplasia (LGD) in Barrett's oesophagus (BO) vary widely. Expert histological review of LGD is advised, but limited data are available on its clinical value. This retrospective cohort study aimed to determine the value of an expert pathology panel organised in the Dutch Barrett's Advisory Committee (BAC) by investigating the incidence rates of high-grade dysplasia (HGD) and oesophageal adenocarcinoma (OAC) after expert histological review of LGD. Design: We included all BO cases referred to the BAC for histological review of LGD diagnosed between 2000 and 2011. The diagnosis of the expert panel was related to the histological outcome during endoscopic follow-up. Primary endpoint was development of HGD or OAC. Results: 293 LGD patients (76% men; mean 63 years±11.9) were included. Following histological review, 73% was downstaged to non-dysplastic BO (NDBO) or indefinite for dysplasia (IND). In 27% the initial LGD diagnosis was confirmed. Endoscopic follow-up was performed in 264 patients (90%) with a median follow-up of 39 months (IQR 16–72). For confirmed LGD, the risk of HGD/OAC was 9.1% per patient-year. Patients downstaged to NDBO or IND had a malignant progression risk of 0.6% and 0.9% per patient-year, respectively. Conclusions: Confirmed LGD in BO has a markedly increased risk of malignant progression. However, the vast majority of patients with community LGD will be downstaged after expert review and have a low progression risk. Therefore, all BO patients with LGD should undergo expert histological review of the diagnosis for adequate risk stratification.